iShares Core High Dividend ETF vs Indivior Pharmaceuticals Inc. Common Stock — how do they compare? iShares Core High Dividend ETF trades at $29.56 (market cap $15.11B), while Indivior Pharmaceuticals Inc. Common Stock trades at $34.01 (market cap $4.18B). The key difference: iShares Core High Dividend ETF is far larger — about 3.6× Indivior Pharmaceuticals Inc. Common Stock's market cap, and iShares Core High Dividend ETF is trading nearer its 52-week high, Indivior Pharmaceuticals Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core High Dividend ETF for 118 Days and Indivior Pharmaceuticals Inc. Common Stock for 0 Days on average.
| HDV | INDV | |
|---|---|---|
Market Cap | $15.11B | $4.18B |
Volume | 2,559,662 | 1,819,746 |
52-Week High | $29.93 | $41.83 |
52-Week Low | $23.64 | $24.09 |
Typical Hold Time | 118 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $4.47B |
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $29.15, up 0.28% with a bullish technical signal from moving averages. The ETF recently underwent a significant sector rebalance, reducing healthcare exposure while increasing energy, staples, and utilities. Technical indicators show strong momentum with RSI at 66.71 suggesting neutral conditions, while ADX readings indicate a strong trend. Recent dividend distributions of $0.10 and $0.06 demonstrate the fund's income-focused strategy.
The ETF's concentrated sector allocation (62% in three sectors) presents both opportunity and risk. While the 3% yield attracts income investors, the reduced diversification may increase vulnerability to sector-specific headwinds. Technical strength supports near-term upside, but investors should weigh the trade-off between current income and long-term growth potential given the sector concentration.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →Indivior Pharmaceuticals, Inc. is a pharmaceutical company focused on treatments for opioid use disorder and other addiction-related conditions, including its Suboxone film and tablet products.
Read more on INDV →